Banner - NPPA Connect

|Videos|January 19, 2023

Optimizing Patient Outcomes with JAK Inhibitors

Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD

Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.

Episodes in this series

EP. 1 Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

EP. 1 Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments

EP. 2 Atopic Dermatitis Treatment Biological Targets

EP. 2 Atopic Dermatitis Treatment Biological Targets

EP. 3 Use of JAK Inhibitors in Clinical Practice

EP. 3 Use of JAK Inhibitors in Clinical Practice

EP. 4 Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

EP. 4 Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management

EP. 5 Final Thoughts for Atopic Dermatitis Treatment

EP. 5 Final Thoughts for Atopic Dermatitis Treatment

EP. 6 Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 6 Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 7 Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 7 Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 8 Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 8 Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 9 Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 9 Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 10 Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 10 Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis

EP. 11 Expert Perspective on the Care of Patients with Atopic Dermatitis

EP. 11 Expert Perspective on the Care of Patients with Atopic Dermatitis

EP. 12 Role of Disease Severity in Topical vs Systemic AD Treatment

EP. 12 Role of Disease Severity in Topical vs Systemic AD Treatment

EP. 13 Efficacy and Safety of JAK inhibitors for AD

EP. 13 Efficacy and Safety of JAK inhibitors for AD

EP. 14 Optimizing Patient Outcomes with JAK Inhibitors

EP. 14 Optimizing Patient Outcomes with JAK Inhibitors

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Rezpegaldesleukin Improves Atopic Dermatitis in Phase 2b Trial

ByShannon Heaning, Content Associate

August 25th 2026

The Multibillion-Dollar Molecule: How Zumilokibart’s Phase 2 Success Sparked AbbVie’s Acquisition

ByMarie Bosslett, Assistant Editor

August 24th 2026

Lebrikizumab Pregnancy Study Opens for Atopic Dermatitis

ByShannon Heaning, Content Associate

August 20th 2026

GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model

ByShannon Heaning, Content Associate

August 20th 2026

Skin & Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle

ByPatricia Delgado, DNP, AGPCNP, DCNP, PMHNP,Judson A. Brewer, MD, Ph.D.,Shannon Heaning, Content Associate

August 18th 2026

Latest CME

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

Journal Digest: September 2, 2026

Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria

Dermatology Times Launches Derm Nexus Congress for NPs and PAs

Dermatology Times Conferences & Meetings Calendar: September 2026